Home » Stocks » ALBO

Albireo Pharma, Inc. (ALBO)

Stock Price: $36.68 USD -0.10 (-0.27%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
After-hours: $36.45 -0.23 (-0.63%) Feb 24, 5:37 PM
Market Cap 712.22M
Revenue (ttm) 12.02M
Net Income (ttm) -90.36M
Shares Out 15.70M
EPS (ttm) -6.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $36.68
Previous Close $36.78
Change ($) -0.10
Change (%) -0.27%
Day's Open 36.70
Day's Range 36.32 - 37.86
Day's Volume 102,261
52-Week Range 11.26 - 49.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET

GlobeNewsWire - 1 week ago

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of i...

GlobeNewsWire - 1 week ago

– Company outlining large global rare cholestatic liver disease opportunity –

Seeking Alpha - 4 weeks ago

Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications. The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasi...

GlobeNewsWire - 1 month ago

Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases Albireo supports the Alagille syndrome community ...

GlobeNewsWire - 1 month ago

BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of i...

GlobeNewsWire - 1 month ago

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will h...

GlobeNewsWire - 1 month ago

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of i...

GlobeNewsWire - 2 months ago

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced th...

GlobeNewsWire - 2 months ago

- Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients -

GlobeNewsWire - 3 months ago

- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus -

GlobeNewsWire - 3 months ago

- P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 -

GlobeNewsWire - 4 months ago

- Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases-

GlobeNewsWire - 4 months ago

Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases Albireo stands together with the PFIC comm...

GlobeNewsWire - 4 months ago

BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced th...

GlobeNewsWire - 5 months ago

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today...

GlobeNewsWire - 5 months ago

BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today...

InvestorPlace - 5 months ago

Albireo Pharma (ALBO) is in the news Tuesday after positive results from a recent clinical trial sent ALBO stock soaring higher. The post Albireo Pharma News: Why ALBO Stock Is Soaring 45% Tod...

The Motley Fool - 5 months ago

The company reported positive data from a clinical trial.

GlobeNewsWire - 5 months ago

-Highly statistically significant reductions in both pruritus and serum bile acids-

GlobeNewsWire - 5 months ago

— Conference call and webcast to be held at 8:30 a.m. EDT — — Conference call and webcast to be held at 8:30 a.m. EDT —

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Albireo Pharma (ALBO) stock based on the movements in the options market lately.

Zacks Investment Research - 6 months ago

Albireo (ALBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Investment Research - 6 months ago

Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.

GlobeNewsWire - 6 months ago

‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒

Seeking Alpha - 6 months ago

Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials ——  Enrolled first biliary atresia patients in second odevixibat pivotal study ——  Completed two financing transactions ...

GlobeNewsWire - 6 months ago

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...

GlobeNewsWire - 6 months ago

—  Conference call and webcast to be held at 10:00 a.m. ET — 

GlobeNewsWire - 7 months ago

— Program expands access to odevixibat for patients with progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease — — Program expands access to o...

GlobeNewsWire - 7 months ago

— BOLD is first-ever pivotal trial for biliary atresia —

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Albireo (ALBO) stock based on the movements in the options market lately.

Zacks Investment Research - 7 months ago

Albireo Pharma (ALBO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 8 months ago

BOSTON, June 10, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...

GlobeNewsWire - 8 months ago

— Restructured HealthCare Royalty Partners elobixibat royalty monetization agreement nets additional $15M in non-dilutive capital — 

Seeking Alpha - 9 months ago

Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q1 2020 Results - Earnings Call Transcript

Benzinga - 9 months ago

Shares of Albireo Pharma (NASDAQ:ALBO) were flat in pre-market trading after the company reported Q1 results.

GlobeNewsWire - 10 months ago

BOSTON, April 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced...

Seeking Alpha - 10 months ago

Albireo Pharma like so many small biotech names has been hit hard during the recent COVID-19 market meltdown.

GlobeNewsWire - 11 months ago

On track to report topline data mid-2020

Seeking Alpha - 11 months ago

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Albireo Pharma: View Ahead Of Phase 3 Data In Progressive Familial Intrahepatic Cholestasis In Mid-2020

GlobeNewsWire - 1 year ago

BOSTON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...

GlobeNewsWire - 1 year ago

BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...

GlobeNewsWire - 1 year ago

BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...

GlobeNewsWire - 1 year ago

—  Reiterates Top Line Data on Phase 3 in PFIC Expected Mid-2020 — — To Initiate Pivotal Trials in Biliary Atresia and Alagille Syndrome in 2020  —

Seeking Alpha - 1 year ago

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Senior leader with demonstrated experience building high-performing businesses and teams Senior leader with demonstrated experience building high-performing businesses and teams

GlobeNewsWire - 1 year ago

Presentations highlight data on odevixibat’s minimal systemic exposure and Albireo’s proprietary pruritus assessment tools Presentations highlight data on odevixibat’s minimal systemic exposur...

GlobeNewsWire - 1 year ago

BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced...

About ALBO

Albireo Pharma, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treat... [Read more...]

Industry
Biotechnology
CEO
Gary Gemignani
Employees
55
Stock Exchange
NASDAQ
Ticker Symbol
ALBO
Full Company Profile

Financial Performance

In 2019, Albireo Pharma's revenue was $9.64 million, a decrease of -24.36% compared to the previous year's $12.74 million. Losses were -$62.72 million, 36.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Albireo Pharma stock is "Strong Buy." The 12-month stock price forecast is 70.71, which is an increase of 92.78% from the latest price.

Price Target
$70.71
(92.78% upside)
Analyst Consensus: Strong Buy